REG - Eco Animal Health Gp - Share Purchase by Executive Director

ECO Animal HealthAnnouncement

02/12/2024 12:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241202:nRSB4452Oa&default-theme=true

RNS Number : 4452O  Eco Animal Health Group PLC  02 December 2024

2 December 2024

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Share Purchase by Executive Director

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that David Hallas, Chief Executive
Officer, has today purchased 15,500 ordinary shares in the Company ("Ordinary
Shares") at 73.8 pence. Following this, Mr Hallas holds 124,834 Ordinary
Shares, representing 0.18 per cent. of the Company's issued share capital.

-Ends-

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

 1.                          Details of the person discharging managerial responsibilities / person closely
                             associated
 a.                          Name                                       David Hallas

 2.                          Reason for the notification
 a.                          Position/status                            Chief Executive Officer

 b.                          Initial notification                       Initial notification

                             /Amendment

 3.                          Details of the issuer, emission allowance market participant, auction
                             platform, auctioneer or auction monitor
 a.                          Name                                       Eco Animal Health Group Plc
 b.                          LEI                                        2138009XN9DJ3YP70B55
 4.                          Details of the transaction(s): section to be repeated for (i) each type of
                             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                             place where transactions have been conducted
 a.                          Description of the                         Ordinary shares of 5p each.

                             Financial instrument, type of instrument

                             Identification code                        GB0032036807

 b.                          Nature of the transaction                  Purchase of Ordinary Shares
 c.                          Price(s) and volume(s)

Price(s)  Volume(s)

                                                                        73.8p     15,500

 
 d.                          Aggregated information

                             Aggregated volume

                             Price                                      n/a

 e.                          Date of the transaction                    2 December 2024
 f.                          Place of the transaction                   London Stock Exchange

 

d.

Aggregated information

Aggregated volume

Price

 

 

n/a

 

e.

Date of the transaction

2 December 2024

f.

Place of the transaction

London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBDBDDXGGDGSD